$ABBV (AbbVie Inc.)

$ABBV {{ '2015-10-30T13:05:23+0000' | timeago}} • Announcement

Based on its potential pipeline to deliver nearly $30Bil in nominal peak-year sales, $ABBV raised its FY15 adjusted EPS guidance from $4.26 to $4.28 and GAAP EPS from $3.16 to $3.18. $ABBV indicates to launch more than 20 new products through 2020.

$ENTA {{ '2017-11-20T21:52:37+0000' | timeago}} • Announcement

Biotech company $ENTA swung to 4Q17 profit on higher revenue, driven by milestone payments totaling $65MM received following $ABBV's U.S. approval of MAVYRET and EU approval of MAVIRET. Net income was $36.5MM or $1.86 per share in the quarter compared to a net loss of $1.8MM, or $0.09 loss per share a year earlier. Revenue jumped to $75.9MM.

$ABBV {{ '2017-10-27T19:44:43+0000' | timeago}} • Webcast

As $ABBV posted 3Q17 results, it now sees full-year gross margin as a percentage of sales at 80.5% and operating margin at 42.5%. AbbVie also expects full-year net interest expense of approximately $1Bil with an adjusted tax rate of about 19%.

$ABBV {{ '2017-10-27T16:20:17+0000' | timeago}} • Infographic

$ABBV AbbVie, Inc. Earnings AlphaGraphic: Q3 2017 highlights

$ABBV {{ '2017-10-27T12:14:02+0000' | timeago}} • Announcement

$ABBV, as it posted 3Q17 results, declared an 11% hike in the quarterly cash dividend to $0.71 per share, beginning with the dividend payable on Feb. 15, 2018 to shareholders of record as of Jan. 12, 2018.

$ABBV {{ '2017-10-27T12:12:54+0000' | timeago}} • Announcement

As $ABBV posted 3Q17 results, it updated its GAAP diluted EPS guidance for FY17 to $4.27-4.29. AbbVie now expects to deliver adjusted diluted EPS for the full year of $5.53-5.55. The drug giant now sees global HUMIRA sales to approach $21Bil in 2020.

$ABBV {{ '2017-10-27T12:11:23+0000' | timeago}} • Announcement

With worldwide net revenues jumping 8.8% to about $7.0Bil in 3Q17, $ABBV saw net earnings inch up 2% to $1.6Bil or $1.01 per diluted share. Global HUMIRA sales saw a 15% hike while global IMBRUVICA net revenues surged 37% in the quarter.

$ABBV {{ '2017-10-18T16:05:30+0000' | timeago}} • Announcement

$ABBV and Harpoon Therapeutics, a biotechnology company developing novel T-cell recruiting biologic therapies, announced that they have entered an immuno-oncology research collaboration.

$ABBV {{ '2017-09-27T12:14:25+0000' | timeago}} • Announcement

$ABBV announced that the Japanese Ministry of Health, Labor and Welfare has approved MAVIRET, a once-daily, treatment for adults with chronic hepatitis C virus infection. The treatment was also recently granted marketing authorization by the European Commission and approved by the US FDA.

$ABBV {{ '2017-09-22T11:48:04+0000' | timeago}} • Announcement

$ABBV and $BMY announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC).

$ABBV {{ '2017-09-08T16:14:15+0000' | timeago}} • Announcement

$ABBV's BoD declared a quarterly cash dividend of $0.64 per share. The dividend is payable on Nov. 15, 2017 to stockholders of record on Oct. 13, 2017. Since the company's inception in 2013, $ABBV has increased its dividend by 60%.

$ABBV {{ '2017-09-06T15:45:07+0000' | timeago}} • Announcement

$ABBV, in cooperation with $NBIX, has submitted a New Drug Application to the FDA for elagolix, an investigational, orally administered gonadotropin-releasing hormone antagonist, being evaluated for the management of endometriosis with associated pain. The pain includes daily menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse.

$ABBV {{ '2017-08-04T18:18:09+0000' | timeago}} • Announcement

The FDA approved $ABBV’s Mavyret to treat adults with chronic hepatitis C virus across all major genotypes (GT1-6). It is an 8-week treatment for patients without cirrhosis and who are new to treatment. Up to 95% of HCV patients in the U.S. may be eligible for the new cure, including those with compensated cirrhosis and limited treatment options.

$ABBV {{ '2017-08-03T13:59:03+0000' | timeago}} • Announcement

$ABBV got the FDA nod for Imbruvica (Ibrutinib) used for treating adult patients with chronic graft-versus-host-disease after failure of one or more treatment. This is the first drug approved to treat the disease, a serious fallout of stem cell or bone marrow transplant. It was co-developed by Pharmacyclics, an AbbVie company, and Janssen Biotech.

$ENTA {{ '2017-07-28T21:01:27+0000' | timeago}} • Announcement

$ENTA said the European Commission (EC) has granted $ABBV marketing authorization for Maviret (glecaprevir/pibrentasvir) for treatment of chronic hepatitis C virus (HCV) infection across all major genotypes. $ENTA expects to receive a $25MM milestone payment from $ABBV.

$ABBV {{ '2017-07-28T15:50:59+0000' | timeago}} • Infographic

$ABBV AbbVie, Inc. Earnings AlphaGraphics: Q2 2017 highlights

$ABBV {{ '2017-07-28T12:13:15+0000' | timeago}} • Announcement

Global HUMIRA sales for $ABBV rose 13.7% in 2Q17, while Global IMBRUVICA net revenues jumped 42.6%. The gross margin ratio in the second quarter was 78.0%, with adjusted gross margin ratio at 82.3%.

$ABBV {{ '2017-07-28T12:04:31+0000' | timeago}} • Announcement

While posting 2Q17 results, $ABBV confirmed its GAAP diluted EPS guidance for FY17 of $4.55-4.65. AbbVie expects to deliver adjusted diluted EPS of $5.44 to $5.54, representing growth of 13.% at the mid-point.

$ABBV {{ '2017-07-28T12:02:43+0000' | timeago}} • Announcement

With the biopharma giant's net revenues up 7.6% to $6.9Bil in 2Q17, $ABBV's net earnings soared 19% to $1.9Bil or $1.19 per share.  Adjusted diluted EPS was $1.42, up 12.7% in the quarter.

$ABBV {{ '2017-07-21T16:09:32+0000' | timeago}} • Announcement

$ABBV received positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for Humira (adalimumab) for the treatment of chronic non-infectious anterior uveitis in pediatric patients. Uveitis is an inflammation of the uvea, which includes the iris, choroid, and the ciliary body in eye.

$PRGO {{ '2017-07-17T13:30:02+0000' | timeago}} • Announcement

$PRGO received final approval from the FDA for its AB rated Abbreviated New Drug Application referencing $ABBV's Androgel Topical Gel, 1.62% packets. The gel is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

Recent Transcripts

OPK (Opko Health, Inc.)
Wednesday, November 8 2017 - 9:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
NKTR (Nektar Therapeutics)
Tuesday, November 7 2017 - 10:00pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, November 7 2017 - 1:00pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, November 6 2017 - 9:30pm
CAH (Cardinal Health, Inc.)
Monday, November 6 2017 - 1:30pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
BDX (Becton, Dickinson and Company)
Thursday, November 2 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
AGIO (Agios Pharmaceuticals, Inc.)
Wednesday, November 1 2017 - 12:00pm
ACOR (Acorda Therapeutics, Inc.)
Tuesday, October 31 2017 - 12:30pm
ABBV (AbbVie Inc.)
Friday, October 27 2017 - 1:00pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm
AMGN (Amgen Inc)
Wednesday, October 25 2017 - 9:00pm
VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, October 25 2017 - 8:30pm
BIIB (Biogen Inc.)
Tuesday, October 24 2017 - 12:30pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm

AlphaGraphics you may like